MedPath

CiNPWT Lower Extremity Amputations (Closed Incision Neagtive Pressure Wound Therapy)

Phase 1
Not yet recruiting
Conditions
Wound Dehiscence
Wound Heal
Interventions
Procedure: Standard of Care group
Device: CINPWT
Registration Number
NCT06493539
Lead Sponsor
University of Southern California
Brief Summary

The objective of this study is to evaluate prospectively the effect of a novel application of Closed Incision Negative Pressure Wound Therapy(CiNPWT), as delivered by the V.A.C. Ulta™ Therapy System (3M, USA) in individuals who have undergone a Lower Extremity Amputation(LEA) compared with standard of care compression wrapping and wound care post-LEA.

This a pilot-controlled exploratory trial including approximately 6-10 individuals who have undergone LEA (trans-metatarsal or higher) randomized between intervention (novel application of CiNPWT) and a control group (standard care).

Detailed Description

The objective of this study is to evaluate prospectively the effect of a novel application of Closed Incision Negative Pressure Wound Therapy (CiNPWT), as delivered by the V.A.C. Ulta™ Therapy System (3M, USA) in individuals who have undergone a Lower Extremity Amputation (LEA) compared with standard of care compression wrapping and wound care post-LEA.

Specific objectives:

1. Collect demographics and relevant data (e.g., risk factors and comorbidities) to compare intervention and control groups.

2. Measure post-surgical outcomes and compare both groups.

STUDY DESIGN

This a pilot-controlled exploratory trial including approximately 6-10 individuals who have undergone LEA (trans-metatarsal or higher) randomized between intervention (novel application of CiNPWT) and a control group (standard care).

DEVICE INFORMATION

The V.A.C. Ulta™ Therapy System (3M, USA) is a non-invasive wound closure system that uses controlled, localized negative pressure to promote healing in chronic and acute wounds. The subatmospheric (ie. negative) pressure system uses latex-free and sterile polyurethane or polyvinyl alcohol foam dressings that are individualized at the bedside to the appropriate size for every patient, and then covered with an adhesive drape to create an airtight seal. A SensaT.R.A.C.™ Pad directly contacts the foam dressing, and accurately senses, monitors, and maintains the target pressure at the wound site to provide controlled negative pressure. Tubing attached to the SensaT.R.A.C.™ Pad connects to a fluid collection canister contained in a programmable, portable, computer-controlled vacuum pump creating negative pressure at the wound surface interface.

Amputation (and revision/re-amputation) is a resection of a segment of a limb through a bone or through a joint.

Major amputation: Any resection proximal to the ankle.

Major amputation levels:

TT = transtibial amputation: amputation through the tibia and fibula (frequently referred to as "below knee amputation").

KD = knee disarticulation: amputation through the knee (frequently referred to as "through knee amputation").

TF = transfemoral amputation: amputation through the femur (frequently referred to as "above knee amputation").

Minor amputation: Any resection distal to the ankle.

Minor amputation levels:

TMA= transmetartarsal amputation.

The level will be determined using the electronic medical record of the patients and by the health care providers observations.

Wound dehiscence (partial or total) is a surgery complication where the incision reopens. Clinically reported by the health care providers. This will be also evaluated with digital photographs.

Infection at the surgical site and/or cellulitis of the residual limb are pathological states caused by invasion and multiplication of microorganisms in host tissues accompanied by tissue destruction and/or a host inflammatory response. This is usually based on soft tissue infection clinical criteria from Infectious Disease Society of America (IDSA) and will be reported by the health care provider.

Closed wound, defined as complete epithelialization at the surgical site, will be based on the health provider's clinical decision combined with medical record documentation. Determination is based on data from wound assessments and photographs performed by the treating clinician and documented in the Tissue Analytics wound imaging software. Photographs will be taken during patient visits (no more than 3x/wk) and if present, wound size, and tissue color percentages will be calculated by Tissue Analytics software. Any wound depth present will be measured manually by the treating therapist and entered into the Tissue Analytics system. Additional wound assessment characteristics that will be documented include periwound color and condition, drainage type or amount, and tissue type assessment. Agreement between clinician's documentation of closure and photographic measurements will be used to ascertain time to closure.

The tolerability/acceptability of CiNPWT will be measured:

* Pain which is a physical suffering or discomfort caused by CiNPWT is usually reported by the patient using the visual analogue scale at each visit.

* Anxiety about the treatment using Hamilton Anxiety Rating Scale (HAM-A)

* Quality of life using the Short Form-36 Questionaire

Baseline characteristics, risk factors and comorbidities will be extracted from the electronic medical record and validated with physical examination. Investigations can be done as necessary to complete missing data such as presence/absence of neuropathy, vascular status, etc., using best practice at the initial evaluation. As an example, blood samples will be obtained at the first evaluation to assess Hemoglobin A1c. If a patient is deemed at nutrition risk based on a nutrition screen done by nursing (Malnutrition Screening Tool), a dietitian will be consulted, and dietary supplementation will be initiated as needed.

All unscheduled or emergency visits will be listed.

At each encounter, the time to complete the treatment including dressings and compression (intervention and control) will be recorded by the clinician in the Electronic Medical Record.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control group: Standard of CareStandard of Care groupFollowing amputation, at POD 1, application of standard care (short stretch compression bandages and standard post-operative wound care) daily.
CiNPWT treatment groupCINPWTFollowing amputation, at POD 1, CiNPWT will be applied in an "envelope-like" fashion, incorporating the incison line as well as \~10 cm of intact proximal residual limb tissue. The underlying skin will be protected with a contact layer and the negative pressure foam is applied for maximal surface area coverage. Negative pressure parameters are set to dynamic pressure control therapy (DPC) from -25 mmHg to -125 mmHg with a 2 minute on/2 minute off cycle and the dressing is left in place for three to five days. A patient may always be removed from treatment intervention whenever they wish.
Primary Outcome Measures
NameTimeMethod
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0".Up to 8 weeks

CiNPWT on number of needed physical therapy visits, adverse events, surgical site infection, re-amputation/revision rate, dehiscence, dressing failure, unscheduled/emergency encounters, hospital-acquired pressure injuries.

Number of participants with reduction of edema as assessed using Girth measurements and Grading system.Up to 8 weeks

Measurement of edema reduction using the +1 to +4 grading system as well as girth measurements of lower extremity of using measuring tape.

Number of participants with Greater acceptability, tolerability and convenience as assessed by Short Form 36 and patient provided feedback.Up to 8 weeks

Determine the overall tolerability, acceptability, and convenience of the intervention using Patient surveys and patient provided feedback.

Number of participants with shorter time to ambulation and weight-bearing as measured by a stopwatch.Up to 8 weeks

CiNPWT effect on ambulation by measuring time to ambulation, time to weight-bearing as measured by a stopwatch.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath